The clearance, granted to Fit-Pro KFT (Ltd.) operating as E-Fit, indicates substantial equivalence for its Ultima System and associated accessory packages, suggesting a market entry for non-invasive aesthetic treatments.
The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Fit-Pro KFT (Ltd.), doing business as E-Fit, for its Ultima System (UL-800) and related accessory packages. The decision, dated September 27, 2026, classifies the device as "Substantially Equivalent" via the Traditional 510(k) pathway, signifying its comparability to existing cleared devices on the market.
The cleared components include the core Ultima System (UL-800) alongside specific accessories: the Ultimate Face Package (UL-800-Face-Set), Ultimate Shape Extension Kit 1 (UL-800-Shape-Ext-Kit-1), and Ultimate Shape Extension Kit 2 (UL-800-Shape-Ext-Kit-2). While the specific intended use or technological basis for these devices was not detailed in the public record, the nomenclature suggests applications within aesthetic or body contouring segments.
Regulatory Context and Market Implications
Substantial equivalence clearance, a common route for medical devices, does not require submission of new clinical trial data for efficacy and safety if the device is sufficiently similar to a predicate device. This pathway often indicates an evolution or refinement of existing technology rather than a fundamentally novel approach.
The absence of a specified product code in the FDA's public record prevents a direct comparison to specific predicate devices or a precise understanding of its classification. However, the clearance allows E-Fit to market and sell the Ultima System in the United States, positioning it to compete in a growing non-invasive aesthetic device sector.
The "Substantially Equivalent" designation means the Ultima System is considered as safe and effective as a legally marketed device already on the market.
Undisclosed Details
Specific clinical data supporting the device, if any were submitted, are not publicly disclosed within the 510(k) summary. Similarly, details regarding the technology, mechanism of action, or the precise indications for use for the Ultima System and its accessory packages have not been made public at the time of this report. E-Fit has not yet issued a press release or made public statements detailing its commercialization strategy, pricing, or target clinician demographic.
